Convertible Notes (Details 2) (USD $)
|
12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
Carrying Amount
|
Dec. 31, 2012
Carrying Amount
|
Dec. 31, 2013
Fair Value
|
Dec. 31, 2012
Fair Value
|
Dec. 31, 2013
4.75% Convertible Senior Notes due 2015
|
Dec. 31, 2012
4.75% Convertible Senior Notes due 2015
|
Dec. 31, 2013
4.75% Convertible Senior Notes due 2015
Carrying Amount
|
Dec. 31, 2012
4.75% Convertible Senior Notes due 2015
Carrying Amount
|
Dec. 31, 2013
4.75% Convertible Senior Notes due 2015
Fair Value
|
Dec. 31, 2012
4.75% Convertible Senior Notes due 2015
Fair Value
|
Dec. 31, 2013
4.75% Convertible Senior Notes due 2015
Baker Entities
|
Aug. 31, 2013
Pfizer Convertible Subordinated Note due 2014
|
Dec. 31, 2013
Pfizer Convertible Subordinated Note due 2014
|
Dec. 31, 2012
Pfizer Convertible Subordinated Note due 2014
|
Dec. 31, 2012
Pfizer Convertible Subordinated Note due 2014
Carrying Amount
|
Dec. 31, 2012
Pfizer Convertible Subordinated Note due 2014
Fair Value
|
Oct. 31, 2007
Pfizer Convertible Subordinated Note due 2014
Collaborative Research and License Agreement with Pfizer
|
Aug. 31, 2013
Pfizer Convertible Subordinated Note due 2014
Collaborative Research and License Agreement with Pfizer
|
Nov. 14, 2013
0.375% convertible senior notes due 2018 and 1.25% convertible senior notes due 2020
|
Nov. 14, 2013
0.375% Convertible Senior Notes due 2018
|
Dec. 31, 2013
0.375% Convertible Senior Notes due 2018
|
Dec. 31, 2013
0.375% Convertible Senior Notes due 2018
Carrying Amount
|
Dec. 31, 2013
0.375% Convertible Senior Notes due 2018
Fair Value
|
Nov. 14, 2013
0.375% Convertible Senior Notes due 2018
Baker Entities
|
Nov. 14, 2013
1.25% Convertible Senior Notes due 2020
|
Dec. 31, 2013
1.25% Convertible Senior Notes due 2020
|
Dec. 31, 2013
1.25% Convertible Senior Notes due 2020
Carrying Amount
|
Dec. 31, 2013
1.25% Convertible Senior Notes due 2020
Fair Value
|
Nov. 14, 2013
1.25% Convertible Senior Notes due 2020
Baker Entities
|
Dec. 31, 2012
Pfizer convertible subordinated note due 2013
|
Feb. 28, 2006
Pfizer convertible subordinated note due 2013
Collaborative Research and License Agreement with Pfizer
|
Dec. 31, 2012
Pfizer convertible subordinated note due 2013
Collaborative Research and License Agreement with Pfizer
|
|
Convertible Notes | ||||||||||||||||||||||||||||||||||
Convertible senior notes | $ 661,567,000 | $ 322,043,000 | $ 84,193,000 | $ 322,043,000 | $ 556,272,000 | $ 798,040,000 | $ 301,037,000 | $ 448,350,000 | $ 276,337,000 | $ 454,913,000 | ||||||||||||||||||||||||
Convertible subordinated notes | 9,033,000 | 9,033,000 | 13,573,000 | |||||||||||||||||||||||||||||||
Long-term debt, noncurrent | 661,567,000 | 331,076,000 | 1,459,535,000 | 811,613,000 | ||||||||||||||||||||||||||||||
Interest rate of debt (as a percent) | 4.75% | 4.75% | 0.00% | 0.375% | 1.25% | |||||||||||||||||||||||||||||
Aggregate principal amount of notes | 10,000,000 | 375,000,000 | 250,000,000 | 375,000,000 | 250,000,000 | 10,000,000 | ||||||||||||||||||||||||||||
Number of days within 30 consecutive trading days in which the price of the entity's common stock must exceed the conversion price for the notes to be converted | 20 days | |||||||||||||||||||||||||||||||||
Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible | 30 days | |||||||||||||||||||||||||||||||||
Percentage of the closing sales price of common stock that the conversion price must exceed in order for the notes to be convertible (as a percent) | 130.00% | |||||||||||||||||||||||||||||||||
Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period | 5 days | |||||||||||||||||||||||||||||||||
Number of consecutive trading days before five consecutive business days during the note measurement period | 5 days | |||||||||||||||||||||||||||||||||
Percentage of the trading price to the product of the last reported sale price of the common stock and the conversion rate, maximum (as a percent) | 98.00% | |||||||||||||||||||||||||||||||||
Conversion ratio, number of shares per principal amount | 0.1139601 | 0.0193207 | 0.0193207 | |||||||||||||||||||||||||||||||
Conversion price per share (in dollars per share) | $ 8.78 | $ 6.84 | $ 51.76 | $ 51.76 | $ 6.84 | |||||||||||||||||||||||||||||
Repurchase price as a percentage of principal | 100.00% | 100.00% | 100.00% | |||||||||||||||||||||||||||||||
Liability on notes on the date of issuance | 118,600,000 | 299,400,000 | 274,800,000 | |||||||||||||||||||||||||||||||
Equity component in convertible notes | 381,400,000 | 75,600,000 | 100,200,000 | |||||||||||||||||||||||||||||||
Carrying value of notes | 100,700,000 | |||||||||||||||||||||||||||||||||
Aggregate principal amount of notes that can be converted into common stock | 10,000,000 | 10,000,000 | ||||||||||||||||||||||||||||||||
Common stock issued in exchange of notes (in shares) | 21,208,303 | 1,025,641 | 1,461,496 | |||||||||||||||||||||||||||||||
Aggregate principal amount of notes exchanged | 186,000,000 | |||||||||||||||||||||||||||||||||
Cash used to fund redemption of notes | 499,994,000 | 11,500,000 | ||||||||||||||||||||||||||||||||
Debt exchange expense | 11,500,000 | |||||||||||||||||||||||||||||||||
Net proceeds from issuance of notes | 728,696,000 | 500,000,000 | ||||||||||||||||||||||||||||||||
Reduction in additional paid-up capital | 381,400,000 | |||||||||||||||||||||||||||||||||
Repurchase of notes | 117,300,000 | |||||||||||||||||||||||||||||||||
Loss on debt repurchase | $ (17,934,000) | $ 17,900,000 |